Polymorphisms of apolipoprotein E; Outcome and susceptibility in multiple sclerosis

Multiple Sclerosis

Volumn 6, Issue 1, 2000, Pages 32-36

  Weatherby, S J M ^a,d   Mann, C L A ^a   Davies, M B ^a   Carthy, D ^b   Fryer, A A ^a   Boggild, M D ^c   Young, C ^c   Strange, R C ^a   Ollier, W ^b   Hawkins, C P ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b University Medical School   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Apolipoprotein E; Disability; Multiple sclerosis; Polymorphisms; Susceptibility

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALLELISM; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROTEIN POLYMORPHISM;

EID: 0034103705     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245800678827464     Document Type: Article

References (38)

1. Compston A. (1997) Genetic epidemiology of multiple sclerosis. J Neurol, Neurosurgery & Psychiatry 62: 553-561.
2. Dyment DA, Sadnovich AD, Ebers GC. (1997) Genetics of multiple sclerosis. Human Molecular Genetics 6: 1693-1698.
3. Schrijver HM et al. (1999) Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity. Neurology 52: 595-599.
4. Kellar-Wood H et al. (1994) Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Annals of Neurology 36: 109-112.
5. Beffert U (1998) The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Rev 27: 119-142.
6. Laskowitz DT, Horsburgh K, Roses AD. (1998) Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 18: 465-471.
7. Roses AD, Saunders AM. (1997) ApoE, Alzheimer's disease, and recovery from brain stress. Annals of the New York Academy of Sciences 826: 200-212.
8. Boyles JK et al. (1989) A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 83: 1015-1031.
9. Gaillard O et al. (1996) Apolipoprotein E intrathecal synthesis is decreased in multiple sclerosis patients. Annals of Clinical Biochemistry 33: 148-150.
10. Chataway J et al. (1998) The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain 121: 1869-1887.
11. Hogancamp WE, Rodriguez M, Weinshenker BG. (1997) The epidemiology of multiple sclerosis. Mayo Clinic Proceedings 72: 871-878.
12. Arendt T et al. (1997) Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. Journal of Neuroscience 17: 516-529.
13. Karussis D et al. (1999) Increased Susceptibility to Experimental Autoimmune Encephalomyelitis (EAE) in ApoE-Knockout Mice. Neurology 52: A339 (Abstract).
14. Hogh P et al. (1998) Apolipoprotein E (ApoE) and multiple sclerosis (MS): impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. European Journal of Neurology 5: S121 (Abstract).
15. Gervais A et al. (1998) Apolipoprotein E polymorphism in multiple sclerosis. Annals of Clinical Biochemistry 35: 135-136.
16. Rubinsztein DC et al. (1994) Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Molecular & Cellular Probes 8: 519-525.
17. Sylantiev C, Chapman J, Chilkevich O. (1998) The APOE 4 Allele and progression of disability in multiple sclerosis. Neurology 50: A150; P03.060 (Abstract).
18. Dousset V, Gayou A, Brochet B, Iron A. (1998) Apo E polymorphism in multiple sclerosis. Multiple Sclerosis 4: 357 (Abstract).
19. Evangelou N, Jackson M, Beeson D, Palace J. (1999) Association of the APOE e4 allele with disease activity in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 67: 203-205.
20. Weatherby SJ et al. (1999) Severity and Susceptibility of Multiple Sclerosis related to polymorphisms of apolipoprotein E. Journal of Neurology 246: I/21 (Abstract).
21. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 13: 227-231.
22. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
23. Wenham PR, Price WH, Blundell G. (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337: 1158-1159.
24. Weinshenker BG. (1997) The natural history of multiple sclerosis. In: Raine CS, et al, Multiple Sclerosis. Clinical and pathogenetic basis. London: Chapman and Hall, pp 81-89.
25. Runmarker B, Andersson C, Oden A, Andersen O. (1994) Prediction of outcome in multiple sclerosis based on multivariate models. Journal of Neurology 241: 597-604.
26. Thompson AJ et al. (1986) A clinical and laboratory study of benign multiple sclerosis. Quarterly Journal of Medicine 58: 69-80.
27. McAlpine D. (1961) The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 84: 186-203.
28. Weinshenker BG et al. (1997) Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 49: 378-385.
29. Pitas RE et al. (1987) Astrocytes synthesize apolipoprotein E and metabolise apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917: 148-161.
30. Sriram S, Rodriguez M. (1997) Indictment of the microglia as the villain in multiple sclerosis. Neurology 48: 464-470.
31. Egensperger R, Kosel S, von Eitzen U, Graeber MB. (1998) Microglial activation in Alzheimer disease: Association with APOE genotype. Brain Pathology 8: 439-447.
32. Smith KJ, Kapoor R, Felts PA. (1999) Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9: 69-92.
33. Laskowitz DT et al. (1998) Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide pro-duction. Neuroreport 9: 615-618.
34. Miyata M, Smith JD. (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nature Genetics 14: 55-61.
35. Macy M et al. (1983) Suppression of lymphocyte activation by plasma lipoproteins. Cancer Research 43: 2496s-2502s.
36. Laskowitz DT, Goel S, Bennett ER, Matthew WD. (1997) Apolipoprotein E suppresses glial cell secretion of TNF-alpha. Journal of Neuroimmunology 76: 70-74.
37. Chakravarti A. (1999) Population genetics- making sense out of sequence. Nature Genetics 21: 56-60.
38. Frankel WN, Schork NJ. (1996) Who's afraid of epistasis? Nature Genetics 14: 371-373.